Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Jones Trading

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Jones Trading to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

PVLA has been the topic of several other research reports. TD Cowen assumed coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, February 11th. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $43.20.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $27.27 on Monday. The stock has a market cap of $306.00 million, a P/E ratio of -2.25 and a beta of 0.54. The business has a 50 day simple moving average of $19.36. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27.

Institutional Trading of Palvella Therapeutics

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC bought a new stake in Palvella Therapeutics during the 4th quarter valued at $125,000. Toronto Dominion Bank purchased a new stake in Palvella Therapeutics during the 4th quarter worth about $159,000. Geode Capital Management LLC bought a new position in Palvella Therapeutics in the 4th quarter worth about $171,000. Cresset Asset Management LLC purchased a new position in Palvella Therapeutics during the 4th quarter valued at about $251,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Palvella Therapeutics during the fourth quarter valued at about $256,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.